Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acellular pertussis vaccine (CIGB)
- Development stage
- Preclinical
- Lead developer
- Center for Genetic Engineering and Biotechnology
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The acellular pertussis vaccine developed by the Cuban Center for Genetic Engineering and Biotechnology (CIGB) is a recombinant protein subunit vaccine designed for the prevention of whooping cough (pertussis). Unlike traditional whole-cell vaccines that use inactivated *Bordetella pertussis* bacteria, this acellular formulation utilizes specific recombinant antigens, most notably a genetically detoxified pertussis toxin (rPT) produced in the yeast *Pichia pastoris*. This recombinant approach allows for high-purity antigen production and aims to significantly reduce the adverse reactions (such as fever and local swelling) commonly associated with whole-cell pertussis components. The vaccine is currently in development and is intended to be integrated into multi-valent pediatric combination vaccines, such as hexavalent formulations, to simplify immunization schedules while maintaining high protective efficacy.
- Other names
- recombinant acellular pertussis vaccineCIGB acellular pertussis vaccineVacuna acelular contra la tos ferina
Beyond the preview
Go deeper on acellular pertussis vaccine (CIGB).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acellular pertussis vaccine (CIGB).